Colombia sets Kaletra price ceiling
This article was originally published in Scrip
The Colombian government has set a maximum price for Abbott's Kaletra (lopinavir plus ritonavir), reducing the private sector price by around 55%. However, civil society is still pushing for the government to issue a compulsory licence.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.